STRO 227
Alternative Names: STRO-227Latest Information Update: 27 Apr 2026
At a glance
- Originator Sutro Biopharma
- Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates
- Mechanism of Action Apoptosis stimulants; DNA topoisomerase I inhibitors; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 20 Apr 2026 Sutro Biopharma plans to file IND application for Solid tumours in late 2026
- 20 Apr 2026 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical trial in Solid tumours released by Sutro Biopharma
- 17 Apr 2026 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical trial in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)